Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Isoform Specific Regulation of Acute Myeloid Leukemia Maintenance By Wilms Tumor 1

Sandeep Potluri, MA, MBBChir, MRCP, Salam A. Assi, PhD, Suyin Paulynn Chin, PhD, Anetta Ptasinska, PhD, Daniel Coleman, PhD, Peter Cockerill, PhD, Constanze Bonifer, PhD

Blood (2019) 134 (Supplement_1): 1232.

https://doi.org/10.1182/blood-2019-122533

Published: 2019

Journal Articles

A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies

Hamid Bolouri, PhD, Benjamin K. Johnson, PhD, Rhonda E. Ries, MA, Laura Pardo, Tiffany A. Hylkema, BS, Wanding Zhou, PhD, Jenny L. Smith, MSc, MD, Amanda R. Leonti, MS, Allison Kaeding, MD, Michael R. Loken, PhD, Jason E. Farrar, MD, Soheil Meshinchi, MD PhD, Timothy Junius Triche, Jr., PhD

Blood (2019) 134 (Supplement_1): 3768.

https://doi.org/10.1182/blood-2019-123487

Published: 2019

Journal Articles

Overexpression mRNA of HMGA2 and WT1 Genes in Whole Blood Samples As Potential Diagnostic Markers in MPN

Marina Stolyar, Aleksey Gorbenko, Mikhail Mikhalev, Tatiana Olkhovik, Anna Khazieva, Nataliya Belevcova, Kseniya Tabakova, Evgeniy Vasiliev, Igor Olkhovskiy

Blood (2018) 132 (Supplement 1): 5460.

https://doi.org/10.1182/blood-2018-99-110150

Published: 2018

Journal Articles

The Clinical Significance of Monitoring Expression Level of Sil-TAL1 Fusion Gene after Allogeneic Hematopoietic Stem Cell Transplantation

Xiaosu Zhao, Dr., Yan Hong, Yazhen Qin, Yingjun Chang, PhD, Xiaohui Zhang, Lanping Xu, Xiao Jun Huang, MD and, professor

Blood (2016) 128 (22): 5800.

https://doi.org/10.1182/blood.V128.22.5800.5800

Published: 2016

Journal Articles

Comparison Between Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net (ELN)-Certified Assay and Other Methods for Detection of Minimal Residual Disease (MRD) in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation

Christina Rautenberg, MD, Sabrina Pechtel, Barbara Hildebrandt, Beate Betz, Ariane Dienst, MD, Kathrin Nachtkamp, MD, Stefanie Geyh, Pia Verena Schmidt, MD, Claudia Heyn, MD, Mustafa Kondakci, MD, Norbert Gattermann, MD, Rainer Haas, MD, Ulrich Germing, Guido Kobbe, MD, Thomas Schroeder, MD

Blood (2016) 128 (22): 3447.

https://doi.org/10.1182/blood.V128.22.3447.3447

Published: 2016

Journal Articles

Electroporation of Dicer-Substrate siRNA Duplexes Targeting Endogenous TCR Enhance Tumor Killing Activity of Wilms' Tumor 1 (WT1)-Specific TCR-Redirected Cytotoxic T Cells

Diana Campillo-Davo, MSc, Fumihiro Fujiki, PhD, Johan M.J. Van den Bergh, MSc, Evelien L. Smits, PhD, Haruo Sugiyama, MD PhD, Viggo F.I. Van Tendeloo, PhD, Zwi N. Berneman, MD PhD

Blood (2016) 128 (22): 813.

https://doi.org/10.1182/blood.V128.22.813.813

Published: 2016

Journal Articles

Minimal Residual Disease Evaluation By Real-Time Quantitative Polymerase Chain Reaction for Wilms Tumor 1 Gene Expression and Multicolour Flow Cytometry, in Pediatric B Lineage Acute Lymphoblastic Leukemia

Neelam Varma, MBBS, MD, Sandeep R., MD DM, Shano Naseem, MD, Man Updesh Singh Sachdeva, MD, Deepak Bansal, MD, Subhash Varma, MBBS, MD, Pankaj Malhotra, MD MBBS

Blood (2015) 126 (23): 4985.

https://doi.org/10.1182/blood.V126.23.4985.4985

Published: 2015

Journal Articles

Wilms´Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches

Guenther Koehne, MDPhD, Satyajit Kosuri, MD, Ekaterina Doubrovina, MD PhD, Tao Dao, PhD, Andrew Scott, Achim A Jungbluth, MD, Richard J O'Reilly, MD

Blood (2015) 126 (23): 98.

https://doi.org/10.1182/blood.V126.23.98.98

Published: 2015

Journal Articles

Adoptive Transfer of WT1-Specific TCR Gene-Transduced Lymphocytes in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

Isao Tawara, MD PhD, Masahiro Masuya, MD PhD, Shinichi Kageyama, MD PhD, Tetsuya Nishida, MD PhD, Seitaro Terakura, MD PhD, Makoto Murata, MD PhD, Hiroshi Fujiwara, MD PhD, Yoshiki Akatsuka, MD PhD, Hiroaki Ikeda, MD PhD, Yoshihiro Miyahara, MD PhD, Daisuke Tomura, PhD, Ikuei Nukaya, PhD, Kazutoh Takesako, PhD, Nobuhiko Emi, MDPhD, Masaki Yasukawa, MD PhD, Naoyuki Katayama, MD PhD, Hiroshi Shiku, MD PhD

Blood (2015) 126 (23): 97.

https://doi.org/10.1182/blood.V126.23.97.97

Published: 2015

Journal Articles

A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations

Colleen E. Annesley, MD, Amy S. Duffield, MD PhD, Rachel E. Rau, MD, Gregory McCarty, Daniel Magoon, Li Li, MD PhD, Vicki Huff, PhD, Donald Small, MD PhD, David Loeb, MD PhD, Patrick Brown, MD

Blood (2015) 126 (23): 312.

https://doi.org/10.1182/blood.V126.23.312.312

Published: 2015

Journal Articles

Monitoring of Wilms’ Tumor 1 (WT1) Expression in Peripheral Blood (PB) of Patients with Myelodysplastic Syndromes (MDS) By a Standardized European Leukemia Net (ELN)-Certified Assay to Detect Minimal Residual Disease (MRD) and Guide Therapeutic Interventions Following Allogeneic Transplantation

Thomas Schroeder, MD, Sabrina Pechtel, Marius Lamers, Ariane Dienst, Esther Schuler, Elena Rachlis, MD, Nadija Wegener, Andrea Kündgen, Mustafa Kondakci, MD, Roland Fenk, MD, Norbert Gattermann, MD PhD, Rainer Haas, MD, Ulrich Germing, Guido Kobbe, MD

Blood (2014) 124 (21): 4661.

https://doi.org/10.1182/blood.V124.21.4661.4661

Published: 2014

Journal Articles

Leukemogenic Wilms Tumor 1 (WT1) Mutations Enhance Progenitor Self Renewal, Inhibit Terminal Myeloid Differentiation, and Influence Survival in a Mouse Model

Colleen E. Annesley, MD, Rachel E. Rau, MD, Daniel Magoon, BS, Gregory McCarty, David Loeb, MD PhD, Patrick Brown, MD

Blood (2014) 124 (21): 3572.

https://doi.org/10.1182/blood.V124.21.3572.3572

Published: 2014

Journal Articles

Monitoring of Wilms’ Tumor 1 Expression As Minimal Residual Disease in Patients with Acute Myeloid Leukemia to Predict Relapse before and after Allogeneic Stem Cell Transplantation

Remy Dulery, MD, Olivier Nibourel, PhD, Vincent Elsermans, David Beauvais, MD, Arthur Simonnet, MD, Jordan Gauthier, MD, Valérie Coiteux, MD, Leonardo Magro, MD, Bruno Quesnel, MD, Claude Preudhomme, Ibrahim Yakoub-Agha, MD PhD

Blood (2014) 124 (21): 1265.

https://doi.org/10.1182/blood.V124.21.1265.1265

Published: 2014

Journal Articles

Wilms’ Tumor 1 Expression Levels in Bone Marrow after Induction and/or Consolidation Therapy Allow a Better Stratification of Patients and Improves Treatment in Adult AML

Blood (2014) 124 (21): 1036.

https://doi.org/10.1182/blood.V124.21.1036.1036

Published: 2014

Journal Articles

Mutation in Wilms' Tumor 1 Induces DNA Hypermethylation of PRC2 Targets, Blocks Myelomonocytic Differentiation, and Defines a Novel Subtype of AML Responsive to EZH2 Inhibition

Daniel Thomas, MD PhD, Subarna Sinha, PhD, Linda Yu, Namyoung Jung, BS, Bo Dai, PhD, Andrew J Gentles, PhD, Andrew P. Feinberg, MD, David Dill, PhD, Ravindra Majeti, MD PhD

Blood (2014) 124 (21): 780.

https://doi.org/10.1182/blood.V124.21.780.780

Published: 2014

Journal Articles

Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

Blood (2013) 122 (21): 2540.

https://doi.org/10.1182/blood.V122.21.2540.2540

Published: 2013

Journal Articles

WT1 Mutations Are Secondary Events In AML and Show Varying Frequencies Within Genetic Subgroups and Different Impact On Prognosis

Susanne Schnittger, PhD, Christiane Eder, PhD, Tamara Alpermann, Frank Dicker, PhD, Madlen Ulke, Alexander Kohlmann, PhD, Sabrina Kuznia, MSc, Wolfgang Kern, MD, Torsten Haferlach, MD, Claudia Haferlach, MD

Blood (2013) 122 (21): 2542.

https://doi.org/10.1182/blood.V122.21.2542.2542

Published: 2013

Journal Articles

The Presence Of Residual Disease After Induction and/Or Consolidation Therapy Based On Wilms’ Tumor 1 (WT1) Expression Is a Strong Prognostic Factor For Relapse and Survival In AML

Blood (2013) 122 (21): 1329.

https://doi.org/10.1182/blood.V122.21.1329.1329

Published: 2013

Journal Articles

Oncogenic Wilms Tumor 1 (WT1) Mutation Augments Hematopoietic Progenitor Cell Clonogenicity and Promotes Expansion Of The Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment: Implications For WT1-Mediated Leukemogenesis

Colleen E. Annesley, MD, Rachel E. Rau, MD, Daniel Magoon, David Loeb, MD, PhD, Patrick Brown, MD

Blood (2013) 122 (21): 1269.

https://doi.org/10.1182/blood.V122.21.1269.1269

Published: 2013

Journal Articles

Aberrant Expression of the MLL5 , BAALC , ID1 , and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study

Blood (2012) 120 (21): 1407.

https://doi.org/10.1182/blood.V120.21.1407.1407

Published: 2012

NARROW

Isoform Specific Regulation of Acute Myeloid Leukemia Maintenance By Wilms Tumor 1

A Distinct Oncofetal B-Cell Transcriptional Program Is Activated in Infant Acute Myeloid Leukemia and Reveals Novel Therapeutic Strategies

Overexpression mRNA of HMGA2 and WT1 Genes in Whole Blood Samples As Potential Diagnostic Markers in MPN

The Clinical Significance of Monitoring Expression Level of Sil-TAL1 Fusion Gene after Allogeneic Hematopoietic Stem Cell Transplantation

Comparison Between Wilms' Tumor 1 (WT1) Expression Using a Standardized European Leukemia Net (ELN)-Certified Assay and Other Methods for Detection of Minimal Residual Disease (MRD) in MDS and AML Patients after Allogeneic Blood Stem Cell Transplantation

Electroporation of Dicer-Substrate siRNA Duplexes Targeting Endogenous TCR Enhance Tumor Killing Activity of Wilms' Tumor 1 (WT1)-Specific TCR-Redirected Cytotoxic T Cells

Minimal Residual Disease Evaluation By Real-Time Quantitative Polymerase Chain Reaction for Wilms Tumor 1 Gene Expression and Multicolour Flow Cytometry, in Pediatric B Lineage Acute Lymphoblastic Leukemia

Wilms´Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches

Adoptive Transfer of WT1-Specific TCR Gene-Transduced Lymphocytes in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia

A Wilms Tumor 1 (WT1) Mutation Causes Myelodysplastic Syndrome in a Knock-in Mouse Model, and a Mixed Myelodysplastic/Myeloproliferative Neoplam in Double Knock-in Mice with WT1 and FLT3/ITD Mutations

Monitoring of Wilms’ Tumor 1 (WT1) Expression in Peripheral Blood (PB) of Patients with Myelodysplastic Syndromes (MDS) By a Standardized European Leukemia Net (ELN)-Certified Assay to Detect Minimal Residual Disease (MRD) and Guide Therapeutic Interventions Following Allogeneic Transplantation

Leukemogenic Wilms Tumor 1 (WT1) Mutations Enhance Progenitor Self Renewal, Inhibit Terminal Myeloid Differentiation, and Influence Survival in a Mouse Model

Monitoring of Wilms’ Tumor 1 Expression As Minimal Residual Disease in Patients with Acute Myeloid Leukemia to Predict Relapse before and after Allogeneic Stem Cell Transplantation

Wilms’ Tumor 1 Expression Levels in Bone Marrow after Induction and/or Consolidation Therapy Allow a Better Stratification of Patients and Improves Treatment in Adult AML

Mutation in Wilms' Tumor 1 Induces DNA Hypermethylation of PRC2 Targets, Blocks Myelomonocytic Differentiation, and Defines a Novel Subtype of AML Responsive to EZH2 Inhibition

Differential Clinical Impact Of Gene Mutations and Their Combinations In Primary Cytogenetically Normal Acute Myeloid Leukemia (CN-AML)

WT1 Mutations Are Secondary Events In AML and Show Varying Frequencies Within Genetic Subgroups and Different Impact On Prognosis

The Presence Of Residual Disease After Induction and/Or Consolidation Therapy Based On Wilms’ Tumor 1 (WT1) Expression Is a Strong Prognostic Factor For Relapse and Survival In AML

Oncogenic Wilms Tumor 1 (WT1) Mutation Augments Hematopoietic Progenitor Cell Clonogenicity and Promotes Expansion Of The Long-Term Hematopoietic Stem Cell (LT-HSC) Compartment: Implications For WT1-Mediated Leukemogenesis

Aberrant Expression of the MLL5 , BAALC , ID1 , and WT1 Genes Is Associated with Higher Induction Mortality and Poorer Overall Survival in Acute Promyelocytic Leukemia Patients Treated with ATRA and Anthracycline-Based Chemotherapy: An International Consortium On Acute Promyelocytic Leukemia Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only